Business Context and Reporting Period
This Form 8-K Current Report was filed by TriSalus Life Sciences, Inc. on February 9, 2026, covering events occurring on February 3, 2026. The filing addresses changes to the Company's Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Resignation: Dr. Arjun "JJ" Desai resigned from the Board of Directors effective immediately on February 3, 2026. The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Appointment: Michael P. Stansky was appointed to the Board, effective February 4, 2026.
- New Director Profile: Mr. Stansky brings 40 years of investment management and healthcare experience. He will serve on the Audit, Compensation, and Science and Technology Committees.
- Related Party Transactions: No related party transactions requiring disclosure under Item 404(a) of Regulation S-K exist between Mr. Stansky and the Company.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. The document serves solely to disclose the Board composition changes and references a press release issued on February 9, 2026, regarding the appointment.
Investor Verification Checklist
- Verify the effective date of Michael P. Stansky's appointment (February 4, 2026) against the press release attached as Exhibit 99.1.
- Confirm the specific committee assignments for the new director (Audit, Compensation, Science and Technology).
- Review the Company's most recent 10-K or 10-Q for financial metrics, as this 8-K does not contain financial data.
- Check for any subsequent filings regarding the transition of Dr. Desai's responsibilities.